Compare Ascendis Pharma A/S (ASND) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares China Large-Cap ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares China Large-Cap ETF trades at $33.48. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| ASND | FXI | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $41.75 |
52-Week Low | $163.32 | $31.59 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FXI trades at $33.48, up 0.21% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF shows mixed momentum with RSI_6 at 89.10 indicating overbought conditions. Recent news highlights China's push in AI and EVs, with a $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, potentially benefiting FXI's holdings. Support sits at $33, resistance at $34.
Outlook is cautiously optimistic due to China's tech and manufacturing rebound, though risks include U.S.-China tensions and valuation concerns. The ETF lacks current fundamental ratios, but sector growth offers upside if geopolitical and regulatory pressures ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
